Evidence map›Paper›PMID 40932876›Full record

ArticleBlood neoplasia2025

V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML.

Vinod A Pullarkat, Mark Levis, James McCloskey, Gabriel N Mannis, Stephen A Strickland, Amir T Fathi, Tara L Lin, Vijaya R Bhatt, Thuva Vanniyasingam, Divya Chakravarthy and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Vinod A PullarkatDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, CA.
Mark LevisDivision of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.
James McCloskeyDivision of Leukemia, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.
Gabriel N MannisDivision of Hematology, Stanford University Medical Center, Palo Alto, CA.
Stephen A StricklandVanderbilt-Ingram Cancer Center, Nashville, TN.
Amir T FathiMassachusetts General Cancer Center/Harvard Medical School, Boston, MA.
Tara L LinDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.
Vijaya R BhattThe Fred & Pamela Buffett Cancer Center, Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE.
Thuva VanniyasingamCytel Inc, Toronto, ON, Canada.
Divya ChakravarthyJazz Pharmaceuticals, Palo Alto, CA.
Yana LutskaJazz Pharmaceuticals, Philadelphia, PA.
Stefan FaderlJazz Pharmaceuticals, Palo Alto, CA.
Ronald S CheungJazz Pharmaceuticals, Palo Alto, CA.
Harry P ErbaDivision of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preclinical data suggest CPX-351, approved for patients with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes, may exhibit synergy with targeted agents, suggesting a rationale for combining targeted agents with CPX-351 as a chemotherapy backbone. The V-FAST (Vyxeos - First Phase ASsessment With Targeted Agents) phase 1b trial evaluated CPX-351 with the targeted agents venetoclax (arm A), midostaurin (arm B), and enasidenib (arm C) in adults with newly diagnosed AML fit for intensive chemotherapy. The dose exploration phase used a 3+3 design to determine the recommended phase 2 dose (RP2D) for each combination. The expansion phase enrolled additional patients to confirm the RP2D. Primary end points were the RP2D and safety. Secondary end points included initial efficacy assessments. Overall, 57 patients were enrolled (arm A, n = 27; arm B, n = 23; arm C, n = 7). In arms A and B, the RP2D was established: CPX-351 (daunorubicin 44 mg/m

Identifiers

PMID40932876
PMCPMC12418821

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.